| human | Q5 |
| P106 | occupation | researcher | Q1650915 |
| Q55055185 | 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the Ameri |
| Q34633760 | 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines |
| Q34233503 | 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines |
| Q82432332 | 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines |
| Q95411361 | 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines |
| Q43673569 | 2013 ACCF/ACR/ASE/ASNC/SCCT/SCMR appropriate utilization of cardiovascular imaging in heart failure: an executive summary: a joint report of the ACR Appropriateness Criteria ® Committee and the ACCF Appropriate Use Criteria Task Force |
| Q87158350 | 2015 ACR/ACC/AHA/AATS/ACEP/ASNC/NASCI/SAEM/SCCT/SCMR/SCPC/SNMMI/STR/STS Appropriate Utilization of Cardiovascular Imaging in Emergency Department Patients With Chest Pain: A Joint Document of the American College of Radiology Appropriateness Criteri |
| Q59217573 | 2048 The hypertrophic cardiomyopathy phenotype revisited with cardiovasculara magnetic resonance |
| Q59217631 | 2055 Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy |
| Q58804613 | 233 Evidence that post-contrast delayed enhancement identified by cardiovascular magnetic resonance is an arrhythmogenic substrate in hypertrophic cardiomyopathy |
| Q73506863 | 34th Bethesda Conference: Executive summary--can atherosclerosis imaging techniques improve the detection of patients at risk for ischemic heart disease? |
| Q57158457 | A Critical Appraisal of Short-term Endpoints in Acute Heart Failure Clinical Trials |
| Q57628767 | A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial |
| Q53529615 | A head-to-head comparison of infusion and bolus doses of adenosine for stress myocardial contrast echocardiography. |
| Q51487790 | A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction. |
| Q58974673 | ACC/AHA/ASNC Guidelines for the Clinical Use of Cardiac Radionuclide Imaging—Executive Summary |
| Q34230607 | ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 G |
| Q96339147 | Acute Kidney Function Declines in the Context of Decongestion in Acute Decompensated Heart Failure |
| Q44732006 | Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial |
| Q53608079 | Acute resting myocardial perfusion imaging in patients with diabetes mellitus: results from the Emergency Room Assessment of Sestamibi for Evaluation of Chest Pain (ERASE Chest Pain) trial. |
| Q45992147 | Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with H |
| Q85344125 | Advanced heart failure with preserved systolic function in nonobstructive hypertrophic cardiomyopathy: under-recognized subset of candidates for heart transplant |
| Q84193168 | Advancing the research mission of ASNC |
| Q48030220 | Age- and sex-based resource utilisation and costs in patients with acute chest pain undergoing cardiac CT angiography: pooled evidence from ROMICAT II and ACRIN-PA trials |
| Q43977903 | American Society of Nuclear Cardiology position statement on radionuclide imaging in patients with suspected acute ischemic syndromes in the emergency department or chest pain center |
| Q92565487 | An example of medical device-based projection of clinical trial enrollment: Use of electrocardiographic data to identify candidates for a trial in acute coronary syndromes |
| Q37223231 | Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia |
| Q57841280 | Assessment and Significance of Left Ventricular Mass by Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy |
| Q37250170 | Assessment and key targets for therapy in the post-myocardial infarction patient with left ventricular dysfunction |
| Q40575947 | Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. |
| Q100994918 | Association of Volume Overload With Kidney Function Outcomes Among Patients With Heart Failure With Reduced Ejection Fraction |
| Q38380414 | COCATS 4 Task Force 6: Training in Nuclear Cardiology |
| Q52999292 | COCATS 4 Task Force 6: Training in Nuclear Cardiology : Endorsed by the American Society of Nuclear Cardiology. |
| Q99241216 | Can Clinical Predictive Models Identify Patients Who Should Not Receive TAVR? A Systematic Review |
| Q37686799 | Cardiac sympathetic imaging with mIBG in heart failure |
| Q56334560 | Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial |
| Q43850131 | Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association |
| Q38393001 | Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial |
| Q58804598 | Characterization of tissue heterogeneity by contrast-enhanced cardiovascular magnetic resonance imaging is a powerful predictor of ventricular tachyarrhythmias on ambulatory holter ECG in hypertrophic cardiomyopathy |
| Q92529716 | Chronic Conditions in Advanced Cardiac Disease: A Cluster Analysis of Transcatheter Aortic Valve Replacement (TAVR)-Treated Patients |
| Q92489625 | Chronic Heart Failure Is Infrequently Associated With Renal Dysfunction in Hypertrophic Cardiomyopathy |
| Q52321325 | Clinical Spectrum and Management of Heart Failure in Hypertrophic Cardiomyopathy. |
| Q91735790 | Clinical and Economic Implications of Inconclusive Noninvasive Test Results in Stable Patients With Suspected Coronary Artery Disease: Insights From the PROMISE Trial |
| Q44622051 | Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial |
| Q39225978 | Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan |
| Q46547297 | Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction |
| Q44607020 | Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy |
| Q37710255 | Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward |
| Q41628928 | Cocaine-using patients with a normal or nondiagnostic electrocardiogram: single-photon emission computed tomography myocardial perfusion imaging and outcome |
| Q46748419 | Comparison of two doses and dosing regimens of tolvaptan in congestive heart failure |
| Q91965857 | Conceptual Considerations for Device-Based Therapy in Acute Decompensated Heart Failure: DRI2P2S |
| Q94948551 | Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment |
| Q85646381 | Contemporary surgical management of hypertrophic cardiomyopathy, the need for more myectomy surgeons and disease-specific centers, and the Tufts initiative |
| Q44684144 | Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program |
| Q37090868 | Coronary CT Angiography Versus Standard Emergency Department Evaluation for Acute Chest Pain and Diabetic Patients: Is There Benefit With Early Coronary CT Angiography? Results of the Randomized Comparative Effectiveness ROMICAT II Trial |
| Q34290173 | Coronary CT angiography versus standard evaluation in acute chest pain |
| Q104103268 | Coronary Computed Tomography Angiography Compared With Single Photon Emission Computed Tomography Myocardial Perfusion Imaging as a Guide to Optimal Medical Therapy in Patients Presenting With Stable Angina: The RESCUE Trial |
| Q37355583 | Coronary computed tomography angiography for early triage of patients with acute chest pain: the ROMICAT (Rule Out Myocardial Infarction using Computer Assisted Tomography) trial |
| Q104467221 | Cost-effectiveness Analysis of Anatomic vs Functional Index Testing in Patients With Low-Risk Stable Chest Pain |
| Q57649817 | Design of the Rule Out Myocardial Ischemia/Infarction Using Computer Assisted Tomography: a multicenter randomized comparative effectiveness trial of cardiac computed tomography versus alternative triage strategies in patients with acute chest pain i |
| Q53396311 | Design, rationale, and populations of an international outcomes and utilization study of pharmacologic stress SPECT myocardial perfusion imaging in contemporary practice. |
| Q37364994 | Detection of coronary artery disease with perfusion stress echocardiography using a novel ultrasound imaging agent: two Phase 3 international trials in comparison with radionuclide perfusion imaging. |
| Q53070856 | Differences in the association of total versus local coronary artery calcium with acute coronary syndrome and culprit lesions in patients with acute chest pain: The coronary calcium paradox. |
| Q90639013 | Discordances between predicted and actual risk in obese patients with suspected cardiac ischaemia |
| Q37894492 | Drug and device effects on peak oxygen consumption, 6-minute walk distance, and natriuretic peptides as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction |
| Q102059795 | Dual Vasopressin Receptor Antagonism to Improve Congestion in Patients With Acute Heart Failure: Design of the AVANTI Trial |
| Q50060431 | Dual Vasopressin V1a/V2 Antagonism: the Next Step in Neurohormonal Modulation in Patients with Heart Failure? |
| Q38415216 | Early resting myocardial computed tomography perfusion for the detection of acute coronary syndrome in patients with coronary artery disease |
| Q89054719 | Editorial commentary: Two faces of Janus: The complexities of coronary artery calcium density and distribution |
| Q100738920 | Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial |
| Q91995607 | Effect of Smoking on Outcomes of Primary PCI in Patients With STEMI |
| Q52616970 | Effect of Spironolactone on Myocardial Fibrosis and Other Clinical Variables in Patients with Hypertrophic Cardiomyopathy: a Prospective, Randomized Trial. |
| Q89752718 | Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial |
| Q92895000 | Effects of obesity on noninvasive test results in patients with suspected cardiac ischemia: Insights from the PROMISE trial |
| Q34003169 | Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial |
| Q37343857 | Effects of tolvaptan on dyspnoea relief from the EVEREST trials |
| Q39264789 | Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials |
| Q79899796 | Eighth Nuclear Cardiology Invitational Conference Park City, Utah, 2006 |
| Q38654218 | Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Sc |
| Q86637516 | Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Sc |
| Q38654226 | Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 5: Valvular Heart Disease: A Scientific Statement From the American Heart Association and American College of Cardiology |
| Q86637546 | Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 5: Valvular Heart Disease: A Scientific Statement From the American Heart Association and American College of Cardiology |
| Q86637544 | Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 8: Coronary Artery Disease: A Scientific Statement from the American Heart Association and American College of Cardiology |
| Q38654235 | Eligibility and Disqualification Recommendations for Competitive Athletes with Cardiovascular Abnormalities: Task Force 8: Coronary Artery Disease: A Scientific Statement from the American Heart Association and American College of Cardiology |
| Q42359819 | Epicardial and paracardial adipose tissue volume and attenuation - Association with high-risk coronary plaque on computed tomographic angiography in the ROMICAT II trial |
| Q93375434 | Errors in Programming and Coding Affecting Cohorts Included in the Study Deriving and Validating the PROMISE Minimal-Risk Tool |
| Q43724180 | Etiology and pathophysiology of new-onset heart failure: evaluation by myocardial perfusion imaging |
| Q44047878 | Evaluation of a new ultrasound contrast agent (AI-700) using two-dimensional and three-dimensional imaging during acute ischemia |
| Q42078936 | Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction |
| Q123511375 | Flurpiridaz F-18 PET Myocardial Perfusion Imaging in Patients With Suspected Coronary Artery Disease |
| Q36157290 | Future directions for cardiovascular disease comparative effectiveness research: report of a workshop sponsored by the National Heart, Lung, and Blood Institute |
| Q36843352 | Future directions of myocardial fatty acid imaging |
| Q82552457 | Gated SPECT myocardial perfusion imaging for the prediction of incident heart failure an old dog learns a new trick |
| Q81410534 | Gender-based differences in brachial artery flow-mediated vasodilation as an indicator of significant coronary artery disease |
| Q39363833 | Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. |
| Q91803453 | Guideline-Based Referral for Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Is Associated With Excellent Clinical Outcomes |
| Q47782446 | High-Sensitivity Cardiac Troponin I as a Gatekeeper for Coronary Computed Tomography Angiography and Stress Testing in Patients with Acute Chest Pain |
| Q34055948 | High-risk plaque detected on coronary CT angiography predicts acute coronary syndromes independent of significant stenosis in acute chest pain: results from the ROMICAT-II trial |
| Q83037528 | Highlights of the 2005 scientific sessions of the American Society of Nuclear Cardiology: Seattle, Washington, September 29-October 2, 2005 |
| Q41753451 | Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies |
| Q34000763 | Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction |
| Q84201659 | Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance |
| Q83237980 | Hyponatraemia and vasopressin in heart failure: markers or mediators? |
| Q36362963 | Hyponatremia in patients with heart failure |
| Q38380767 | Identification of Patients With Stable Chest Pain Deriving Minimal Value From Noninvasive Testing: The PROMISE Minimal-Risk Tool, A Secondary Analysis of a Randomized Clinical Trial |
| Q47295461 | Identification of patients with stable chest pain deriving minimal value from coronary computed tomography angiography: An external validation of the PROMISE minimal-risk tool |
| Q91144292 | Imaging Coronary Anatomy and Reducing Myocardial Infarction |
| Q57623005 | Imaging Highlights From the European Society of Cardiology, American Society of Nuclear Cardiology, and Heart Failure Society of America |
| Q38222225 | Imaging techniques for the assessment of suspected acute coronary syndromes in the emergency department |
| Q91270218 | Impact of Autonomic Regulation Therapy in Patients with Heart Failure: ANTHEM-HFrEF Pivotal Study Design |
| Q36367412 | Impact of Coronary Calcification on Clinical Management in Patients With Acute Chest Pain |
| Q57628853 | Implantable Cardioverter-Defibrillators in Patients Hospitalized for Heart Failure With Chronically Reduced Left Ventricular Ejection Fraction |
| Q57413975 | Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial |
| Q88250374 | Incorrect Conclusions of a Secondary Analysis |
| Q38838323 | Infarct size, left ventricular function, and prognosis in women compared to men after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: results from an individual patient-level pooled analysis of 10 randomized |
| Q34248663 | Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial |
| Q46212638 | Influence of donor cocaine use on outcome after cardiac transplantation: analysis of the United Network for Organ Sharing Thoracic Registry. |
| Q35660105 | Influence of myocardial ischemia on outcomes in patients with systolic versus non-systolic heart failure |
| Q53187865 | Intermediate-signal-intensity late gadolinium enhancement predicts ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy. |
| Q50981942 | Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. |
| Q99232744 | Invasive Hemodynamic Assessment and Classification of In-Hospital Mortality Risk Among Patients With Cardiogenic Shock |
| Q44275977 | Iodofiltic acid I 123 (BMIPP) fatty acid imaging improves initial diagnosis in emergency department patients with suspected acute coronary syndromes: a multicenter trial |
| Q59255114 | Is the 12-lead electrocardiogram of value in the prognostic assessment of patients with hypertrophic cardiomyopathy? |
| Q38963414 | Lack of Phenotypic Differences by Cardiovascular Magnetic Resonance Imaging in MYH7 (β-Myosin Heavy Chain)- Versus MYBPC3 (Myosin-Binding Protein C)-Related Hypertrophic Cardiomyopathy |
| Q55643045 | Late gadolinium enhancement score (LGE-Score) for prediction of extensive late gadolinium enhancement in hypertrophic cardiomyopathy. |
| Q37828258 | Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. |
| Q91863737 | Long-term health outcomes and cost-effectiveness of coronary CT angiography in patients with suspicion for acute coronary syndrome |
| Q44389057 | MIBG imaging for selecting heart failure patients for defibrillator therapy: a first step |
| Q38471904 | Metabolic imaging with beta-methyl-p-[(123)I]-iodophenyl-pentadecanoic acid identifies ischemic memory after demand ischemia |
| Q84352868 | Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy |
| Q59254977 | Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy |
| Q80418434 | Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction |
| Q53665239 | Myocardial perfusion imaging for evaluation and triage of patients with suspected acute cardiac ischemia: a randomized controlled trial. |
| Q43939852 | Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis |
| Q40879492 | Neuronal dysfunction and medical therapy in heart failure: can an imaging biomarker help to "personalize" therapy? |
| Q35562100 | New concepts in post-infarction ventricular remodeling |
| Q92197222 | Non-invasive fractional flow reserve derived from coronary computed tomography angiography in patients with acute chest pain: Subgroup analysis of the ROMICAT II trial |
| Q35055707 | Noninvasive assessment of left ventricular remodeling: concepts, techniques, and implications for clinical trials |
| Q50021030 | Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide |
| Q36770714 | Novel neurohormonal antagonist strategies: vasopressin antagonism, anticytokine therapy, and endothelin antagonism in patients who have heart failure |
| Q57841055 | Obesity and its Association to Phenotype and Clinical Course in Hypertrophic Cardiomyopathy |
| Q57418111 | Occurrence and Frequency of Arrhythmias in Hypertrophic Cardiomyopathy in Relation to Delayed Enhancement on Cardiovascular Magnetic Resonance |
| Q33705061 | One-year outcomes of out-of-hospital administration of intravenous glucose, insulin, and potassium (GIK) in patients with suspected acute coronary syndromes (from the IMMEDIATE [Immediate Myocardial Metabolic Enhancement During Initial Assessment an |
| Q34204296 | Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial |
| Q35759198 | Outcomes of anatomical versus functional testing for coronary artery disease |
| Q37465140 | Outcomes research in cardiovascular imaging: report of a workshop sponsored by the National Heart, Lung, and Blood Institute |
| Q37335877 | Outcomes research in cardiovascular imaging: report of a workshop sponsored by the National Heart, Lung, and Blood Institute. |
| Q51806504 | Outcomes research in cardiovascular imaging: report of a workshop sponsored by the National Heart, Lung, and Blood Institute. |
| Q51821422 | Outcomes research in cardiovascular imaging: report of a workshop sponsored by the National Heart, Lung, and Blood Institute. |
| Q36362967 | Overview of vasopressin receptor antagonists in heart failure resulting in hospitalization |
| Q33708527 | PROspective Multicenter Imaging Study for Evaluation of chest pain: rationale and design of the PROMISE trial |
| Q52019426 | Peripheral vascular endothelial function correlates with exercise capacity in cardiac transplant recipients. |
| Q35047860 | Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography |
| Q57396271 | Phase III clinical trial end points in acute heart failure syndromes: A virtual roundtable with the acute heart failure syndromes international working group |
| Q97680382 | Phase-III Clinical Trial of Fluorine-18 Flurpiridaz Positron Emission Tomography for Evaluation of Coronary Artery Disease |
| Q91319962 | Predictive Model for High-Risk Coronary Artery Disease |
| Q90303180 | Pretest probability for patients with suspected obstructive coronary artery disease: re-evaluating Diamond-Forrester for the contemporary era and clinical implications: insights from the PROMISE trial |
| Q47801250 | Prevalence and clinical profile of myocardial crypts in hypertrophic cardiomyopathy |
| Q43954826 | Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy |
| Q47333818 | Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy |
| Q78851256 | Prevention and reversal of left ventricular remodeling: summation |
| Q35157804 | Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy |
| Q38378366 | Prognostic Value of Noninvasive Cardiovascular Testing in Patients With Stable Chest Pain: Insights From the PROMISE Trial (Prospective Multicenter Imaging Study for Evaluation of Chest Pain). |
| Q56973319 | Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy |
| Q41845098 | Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach |
| Q45285140 | Quantitative instruments for predicting risk ... and benefit |
| Q34883572 | Radionuclide imaging in heart failure: assessing etiology and outcomes and implications for management |
| Q44735739 | Randomized, controlled dose-ranging study of the selective adenosine A2A receptor agonist binodenoson for pharmacological stress as an adjunct to myocardial perfusion imaging |
| Q39692335 | Randomized, controlled evaluation of short- and long-term benefits of heart failure disease management within a diverse provider network: the SPAN-CHF trial |
| Q43124593 | Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction |
| Q89918114 | Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserve |
| Q79194117 | Rationale and design of CASPER: compliance and quality of life study comparing once-daily carvedilol CR and twice-daily carvedilol IR in patients with heart failure |
| Q33724340 | Rationale and design of the Randomized Evaluation of patients with Stable angina Comparing Utilization of noninvasive Examinations (RESCUE) trial |
| Q46478452 | Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). |
| Q38737940 | Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations |
| Q45939197 | Regional Validation and Recalibration of Clinical Predictive Models for Patients With Acute Heart Failure. |
| Q35055712 | Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction. |
| Q92666233 | Relation between therapy-induced changes in natriuretic peptide levels and long-term therapeutic effects on mortality in patients with heart failure and reduced ejection fraction |
| Q40811915 | Relationship Between Infarct Size and Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials |
| Q38746989 | Relationship between therapeutic effects on infarct size in acute myocardial infarction and therapeutic effects on 1-year outcomes: A patient-level analysis of randomized clinical trials |
| Q57418115 | Reply |
| Q91236893 | Reply: Atrial Fibrillation in Hypertrophic Cardiomyopathy |
| Q88512856 | Reply: Chronic Kidney Disease Contributing to Dyspnea in Patients With Heart Failure |
| Q57842080 | Response to Letter Regarding Article, “Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction” |
| Q41698142 | Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience |
| Q100996724 | Return to Play for Athletes After Coronavirus Disease 2019 Infection-Making High-Stakes Recommendations as Data Evolve |
| Q81405267 | Right ventricular involvement in hypertrophic cardiomyopathy |
| Q43731197 | Risk stratification and outcome of patients with hypertrophic cardiomyopathy >=60 years of age. |
| Q35570624 | Role of beta-blocker therapy in the post-myocardial infarction patient with and without left ventricular dysfunction |
| Q57631035 | Role of β-Blocker Therapy in the Postmyocardial Infarction Patient With and Without Left Ventricular Dysfunction Consensus Guideline |
| Q53097363 | Safety of coronary CT angiography and functional testing for stable chest pain in the PROMISE trial: A randomized comparison of test complications, incidental findings, and radiation dose. |
| Q81616822 | Screening the population for coronary artery disease: is it like screening for cancer? |
| Q35234629 | Sensitive troponin assays in patients with suspected acute coronary syndrome: Results from the multicenter rule out myocardial infarction using computer assisted tomography II trial |
| Q36968452 | Sex Differences in Functional and CT Angiography Testing in Patients With Suspected Coronary Artery Disease |
| Q37120192 | Sex differences in the effectiveness of early coronary computed tomographic angiography compared with standard emergency department evaluation for acute chest pain: the rule-out myocardial infarction with Computer-Assisted Tomography (ROMICAT)-II Tr |
| Q39158288 | Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload |
| Q34612162 | Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials |
| Q81765966 | Significance and relation between magnitude of left ventricular hypertrophy and heart failure symptoms in hypertrophic cardiomyopathy |
| Q53485268 | Significance of Late Gadolinium Enhancement at Right Ventricular Attachment to Ventricular Septum in Patients With Hypertrophic Cardiomyopathy. |
| Q57418116 | Significance of Papillary Muscle Abnormalities Identified by Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy |
| Q84585783 | Significance of false negative electrocardiograms in preparticipation screening of athletes for hypertrophic cardiomyopathy |
| Q87838326 | Significance of left ventricular apical-basal muscle bundle identified by cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy |
| Q84517546 | Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy |
| Q33564586 | Study design for the Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care (IMMEDIATE) Trial: A double-blind randomized controlled trial of intravenous glucose, insulin, and potassium for acute coronary |
| Q57628377 | Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial) |
| Q84799593 | Survival after cardiac transplantation in patients with hypertrophic cardiomyopathy |
| Q36101172 | Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome |
| Q39657199 | The Heart Failure Society of America in 2020: a vision for the future |
| Q34778284 | The Occluded Artery Trial (OAT) Viability Ancillary Study (OAT-NUC): influence of infarct zone viability on left ventricular remodeling after percutaneous coronary intervention versus optimal medical therapy alone |
| Q41185307 | The Post-Myocardial Infarction Pacing Remodeling Prevention Therapy (PRomPT) Trial: Design and Rationale |
| Q47299773 | The United Kingdom's National Institute for Health and Care Excellence guideline on chest pain of recent onset: A United States perspective |
| Q43288795 | The case for myocardial ischemia in hypertrophic cardiomyopathy |
| Q35790290 | The historical and conceptual evolution of radionuclide assessment of myocardial viability |
| Q53492368 | The price for probability: Comparing the costs of diagnostic testing strategies. |
| Q26786687 | Tolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF Trials |
| Q42628429 | Training cardiovascular fellows in cardiovascular magnetic resonance and vascular imaging; Current status following the core cardiovascular training symposium (COCATS-2) guidelines |
| Q39171417 | Trials of Imaging Use in the Emergency Department for Acute Chest Pain |
| Q90759633 | Unloading the Left Ventricle Before Reperfusion in Patients With Anterior ST-Segment-Elevation Myocardial Infarction |
| Q40112478 | Use of Coronary Computed Tomographic Angiography Findings to Modify Statin and Aspirin Prescription in Patients With Acute Chest Pain |
| Q47739245 | Use of High-Risk Coronary Atherosclerotic Plaque Detection for Risk Stratification of Patients With Stable Chest Pain: A Secondary Analysis of the PROMISE Randomized Clinical Trial |
| Q35120329 | Use of coronary artery calcium scanning beyond coronary computed tomographic angiography in the emergency department evaluation for acute chest pain: the ROMICAT II trial |
| Q53507975 | Vascular endothelial dysfunction is associated with reversible myocardial perfusion defects in the absence of obstructive coronary artery disease. |
| Q56765793 | Vasopressin V2 Receptor Blockade With Tolvaptan Versus Fluid Restriction in the Treatment of Hyponatremia |
| Q51485770 | Ventricular assist device therapy normalizes inducible nitric oxide synthase expression and reduces cardiomyocyte apoptosis in the failing human heart. |
| Q83704878 | Ventricular remodeling fundamental to the progression (and regression) of heart failure |
| Q79219448 | Ventricular remodeling in heart failure: a credible surrogate endpoint |
| Q46027453 | Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial. |
| Q36278859 | hs-Troponin I Followed by CT Angiography Improves Acute Coronary Syndrome Risk Stratification Accuracy and Work-Up in Acute Chest Pain Patients: Results From ROMICAT II Trial |
| Q26828766 | 2013 ACCF/ACR/ASE/ASNC/SCCT/SCMR appropriate utilization of cardiovascular imaging in heart failure: a joint report of the American College of Radiology Appropriateness Criteria Committee and the American College of Cardiology Foundation Appropriate |
| Q26774798 | 2015 ACR/ACC/AHA/AATS/ACEP/ASNC/NASCI/SAEM/SCCT/SCMR/SCPC/SNMMI/STR/STS Appropriate Utilization of Cardiovascular Imaging in Emergency Department Patients With Chest Pain: A Joint Document of the American College of Radiology Appropriateness Criteri |
Search more.